The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer

The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer

Abstract Background Papillary thyroid cancer (PTC) is the most frequent endocrine tumor. Radioiodine (RAI) treatment is highly effective in these tumors, but up to 60% of metastatic cases become RAI-refractory. Scanty data are available on either the molecular pattern of radioiodine refractory papil...

Full description

Bibliographic Details
Main Authors:	Carla Colombo, Emanuela Minna, Chiara Gargiuli, Marina Muzza, Matteo Dugo, Loris De Cecco, Gabriele Pogliaghi, Delfina Tosi, Gaetano Bulfamante, Angela Greco, Laura Fugazzola, Maria Grazia Borrello
Format:	Article
Language:	English
Published:	BMC 2020-11-01
Series:	Journal of Experimental & Clinical Cancer Research
Subjects:	Thyroid Oncogenes Radioiodine refractory Gene/miRNA profiles Papillary thyroid cancer
Online Access:	http://link.springer.com/article/10.1186/s13046-020-01757-x

Similar Items

Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
by: Yuchen Jin, et al.
Published: (2017-11-01)

CYTOLOGICAL CHARACTERISTICS OF POSTOPERATIVE METASTASES OF PAPILLARY THYROID CANCER DURING THE DEVELOPMENT OF SECONDARY RADIOIODINE REFRACTORINESS
by: Anna Zelinskaya, et al.
Published: (2020-01-01)

RADIOIODINE THERAPY OF PAPILLARY THYROID CANCER, COMPLICATED BY A RADIAL MYELITIS. CLINICAL CASE
by: L. M. Farkhutdinova
Published: (2018-06-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma
by: Arwa Alsaud, et al.
Published: (2020-03-01)

Papillary thyroid microcarcinoma
by: V A Smirnova, et al.
Published: (2015-06-01)

Combined Mutational and Clonality Analyses Support the Existence of Intra-Tumor Heterogeneity in Papillary Thyroid Cancer
by: Marina Muzza, et al.
Published: (2021-06-01)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
by: Dario Tumino, et al.
Published: (2017-11-01)

Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
by: Zohreh Maghsoomi, et al.
Published: (2021-05-01)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
by: Chae Moon Hong, et al.
Published: (2017-10-01)

Simultaneous occurrence of medullary and papillary thyroid microcarcinomas: a case series and review of the literature
by: Adnan Zaina, et al.
Published: (2013-01-01)

Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b)
by: Pedro Weslley Rosario, et al.
Published: (2017-02-01)

CUX2 functions as an oncogene in papillary thyroid cancer
by: Sun Y, et al.
Published: (2018-12-01)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
by: Lorusso L, et al.
Published: (2016-10-01)

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01)

Pre-Therapeutic Measurements of Iodine Avidity in Papillary and Poorly Differentiated Thyroid Cancer Reveal Associations with Thyroglobulin Expression, Histological Variants and Ki-67 Index
by: Joachim N. Nilsson, et al.
Published: (2021-07-01)

Tall-cell variant of papillary thyroid carcinoma: literature review and case reports
by: E. V. Borodavina, et al.
Published: (2020-11-01)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
by: Cristiane J. Gomes-Lima, et al.
Published: (2021-02-01)

Potential of the drug-regulation iodide uptake in patients for prevention of radioiodine-refractory papillary thyroid cancer
by: Dmitriy Kirillovich Fomin, et al.
Published: (2014-11-01)

RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma (PTC)
by: Cristina eRomei, et al.
Published: (2012-04-01)

Radioiodine (131I) therapy in a child with autism spectrum disorder: A complex and demanding task
by: Giovanni Bibbo, et al.
Published: (2019-01-01)

Occurrence of symptomatic meningioma as a second neoplasm in patients with differentiated thyroid cancer treated with radioiodine
by: Nishikant Avinash Damle, et al.
Published: (2012-01-01)

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01)

Recombinant human thyrotropin in radioiodine diagnostics and radioiodine ablation of patients with well-differentiated thyroid cancer: the first experience in Russia
by: Ivan I. Dedov, et al.
Published: (2018-12-01)

Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases
by: Jochen Hammes, et al.
Published: (2018-12-01)

Papillary carcinoma thyroid with rare metastases: A case report and review
by: Ramya Yethadka, et al.
Published: (2016-12-01)

Sudden Development of Subcutaneous Nodules Shortly after Radioiodine Treatment for Thyroid Cancer Caused by Self-Limiting Sarcoidosis
by: Wael Zaher, et al.
Published: (2020-05-01)

Radioiodine-resistant metastases of well-differentiated thyroid cancer, analysis of tumor characteristics and primary surgical intervention
by: M. V. Ostafiychuk, et al.
Published: (2021-10-01)

Comparison of Papillary Thyroid Microcarcinoma and Carcinoma
by: Kamile Gül, et al.
Published: (2009-12-01)

The history of radioiodine therapy beginnings
by: Pavel Olegovich Rumiantsev, et al.
Published: (2016-03-01)

Evaluation of a Number of Blood Biochemical Markers after Radioiodine Therapy in Papillary Thyroid Cancer Patients
by: Mehrossadat Alavi, et al.
Published: (2017-04-01)

Papillary thyroid cancer recurrence 43 Years following Total Thyroidectomy and radioactive iodine ablation: a case report
by: Yaw Amoako-Tuffour, et al.
Published: (2017-10-01)

A rare case of laryngotracheal chondrosarcoma in a patient with past history of radioiodine therapy for thyroid cancer
by: Gholamreza Mohajeri, et al.
Published: (2013-01-01)

Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
by: S.M. Coelho, et al.
Published: (2011-01-01)

Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
by: S.M. Coelho, et al.
Published: (2011-01-01)

Restaging of differentiated thyroid carcinoma with SPECT/CT after radioiodine therapy
by: Mariya Alekseevna Karalkina, et al.
Published: (2015-07-01)

<sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
by: Freba Ahmaddy, et al.
Published: (2021-01-01)

Expression of Notch 1 receptor associated with tumor aggressiveness in papillary thyroid carcinoma
by: Fu H, et al.
Published: (2016-03-01)

Ultrasonographic imaging of papillary thyroid carcinoma variants
by: Jung Hee Shin
Published: (2017-04-01)

Radioiodine-induced oxidative stress in patients with differentiated thyroid carcinoma and effect of supplementation with vitamins C and E and selenium (antioxidants)
by: Pedro Weslley Rosário, et al.
Published: (2016-02-01)